Cargando…

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma

Bevacizumab has been reported to be effective for recurrent glioblastoma. In our hospital, ifosfamide, carboplatin, etoposide (ICE) is the second-line chemotherapy for first recurrence of glioblastoma after temozolomide failure. In the present analysis, we retrospectively investigated the feasibilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Arakawa, Yoshiki, Mizowaki, Takashi, Murata, Daiki, Fujimoto, Koichi, Kikuchi, Takayuki, Kunieda, Takeharu, Takahashi, Jun C., Takagi, Yasushi, Miyamoto, Susumu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Neurosurgical Society 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508722/
https://www.ncbi.nlm.nih.gov/pubmed/24140770
http://dx.doi.org/10.2176/nmc.oa2013-0211
_version_ 1782381982232084480
author Arakawa, Yoshiki
Mizowaki, Takashi
Murata, Daiki
Fujimoto, Koichi
Kikuchi, Takayuki
Kunieda, Takeharu
Takahashi, Jun C.
Takagi, Yasushi
Miyamoto, Susumu
author_facet Arakawa, Yoshiki
Mizowaki, Takashi
Murata, Daiki
Fujimoto, Koichi
Kikuchi, Takayuki
Kunieda, Takeharu
Takahashi, Jun C.
Takagi, Yasushi
Miyamoto, Susumu
author_sort Arakawa, Yoshiki
collection PubMed
description Bevacizumab has been reported to be effective for recurrent glioblastoma. In our hospital, ifosfamide, carboplatin, etoposide (ICE) is the second-line chemotherapy for first recurrence of glioblastoma after temozolomide failure. In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment. Between 2010 and 2012, tumor progressions were diagnosed in consecutive 8 patients who were treated with ICE for the first recurrence of glioblastoma. These patients were administered 3 cycles of 10 mg/kg bevacizumab every two weeks in combination with ICE treatment. The objective response rate of bevacizumab combination was 75% in Neuro-Oncology Working Group (RANO criteria), including complete response and partial response. Median progression free survival (PFS) and median overall survival (OS) after second relapse were 3.7 months (95% confidence interval [CI], 2.5–18.5 months) and 6.0 months (95% CI, 3.2–19.7 months), respectively. The 6-month PFS rates were 25% (95% CI, 0–55.0%). The median OS after initial diagnosis was 23.3 months (95% CI, 16.2–55.8 months). The grade 2 or 3 hematologic adverse events were identified in 7 of 8 patients, most of which might be due to ICE chemotherapy. The results of our retrospective analysis suggest that combination treatment with bevacizumab and ICE may be safe and beneficial in patients with recurrent glioblastoma.
format Online
Article
Text
id pubmed-4508722
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher The Japan Neurosurgical Society
record_format MEDLINE/PubMed
spelling pubmed-45087222015-11-05 Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma Arakawa, Yoshiki Mizowaki, Takashi Murata, Daiki Fujimoto, Koichi Kikuchi, Takayuki Kunieda, Takeharu Takahashi, Jun C. Takagi, Yasushi Miyamoto, Susumu Neurol Med Chir (Tokyo) Special Theme Topic: Treatment of Malignant Brain Tumor Bevacizumab has been reported to be effective for recurrent glioblastoma. In our hospital, ifosfamide, carboplatin, etoposide (ICE) is the second-line chemotherapy for first recurrence of glioblastoma after temozolomide failure. In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment. Between 2010 and 2012, tumor progressions were diagnosed in consecutive 8 patients who were treated with ICE for the first recurrence of glioblastoma. These patients were administered 3 cycles of 10 mg/kg bevacizumab every two weeks in combination with ICE treatment. The objective response rate of bevacizumab combination was 75% in Neuro-Oncology Working Group (RANO criteria), including complete response and partial response. Median progression free survival (PFS) and median overall survival (OS) after second relapse were 3.7 months (95% confidence interval [CI], 2.5–18.5 months) and 6.0 months (95% CI, 3.2–19.7 months), respectively. The 6-month PFS rates were 25% (95% CI, 0–55.0%). The median OS after initial diagnosis was 23.3 months (95% CI, 16.2–55.8 months). The grade 2 or 3 hematologic adverse events were identified in 7 of 8 patients, most of which might be due to ICE chemotherapy. The results of our retrospective analysis suggest that combination treatment with bevacizumab and ICE may be safe and beneficial in patients with recurrent glioblastoma. The Japan Neurosurgical Society 2013-11 2014-10-21 /pmc/articles/PMC4508722/ /pubmed/24140770 http://dx.doi.org/10.2176/nmc.oa2013-0211 Text en © 2013 The Japan Neurosurgical Society This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Special Theme Topic: Treatment of Malignant Brain Tumor
Arakawa, Yoshiki
Mizowaki, Takashi
Murata, Daiki
Fujimoto, Koichi
Kikuchi, Takayuki
Kunieda, Takeharu
Takahashi, Jun C.
Takagi, Yasushi
Miyamoto, Susumu
Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
title Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
title_full Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
title_fullStr Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
title_full_unstemmed Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
title_short Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
title_sort retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma
topic Special Theme Topic: Treatment of Malignant Brain Tumor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508722/
https://www.ncbi.nlm.nih.gov/pubmed/24140770
http://dx.doi.org/10.2176/nmc.oa2013-0211
work_keys_str_mv AT arakawayoshiki retrospectiveanalysisofbevacizumabincombinationwithifosfamidecarboplatinandetoposideinpatientswithsecondrecurrenceofglioblastoma
AT mizowakitakashi retrospectiveanalysisofbevacizumabincombinationwithifosfamidecarboplatinandetoposideinpatientswithsecondrecurrenceofglioblastoma
AT muratadaiki retrospectiveanalysisofbevacizumabincombinationwithifosfamidecarboplatinandetoposideinpatientswithsecondrecurrenceofglioblastoma
AT fujimotokoichi retrospectiveanalysisofbevacizumabincombinationwithifosfamidecarboplatinandetoposideinpatientswithsecondrecurrenceofglioblastoma
AT kikuchitakayuki retrospectiveanalysisofbevacizumabincombinationwithifosfamidecarboplatinandetoposideinpatientswithsecondrecurrenceofglioblastoma
AT kuniedatakeharu retrospectiveanalysisofbevacizumabincombinationwithifosfamidecarboplatinandetoposideinpatientswithsecondrecurrenceofglioblastoma
AT takahashijunc retrospectiveanalysisofbevacizumabincombinationwithifosfamidecarboplatinandetoposideinpatientswithsecondrecurrenceofglioblastoma
AT takagiyasushi retrospectiveanalysisofbevacizumabincombinationwithifosfamidecarboplatinandetoposideinpatientswithsecondrecurrenceofglioblastoma
AT miyamotosusumu retrospectiveanalysisofbevacizumabincombinationwithifosfamidecarboplatinandetoposideinpatientswithsecondrecurrenceofglioblastoma